Efficacy of emicizumab is maintained throughout dosing intervals for bleed prophylaxis

BACKGROUND: Across the HAVEN clinical trial program, the efficacy of emicizumab has been demonstrated in children, adolescents, and adults with hemophilia A, with or without factor VIII inhibitors. After the 4-week loading dose period, emicizumab concentrations are expected to remain at levels that...

Descripción completa

Detalles Bibliográficos
Autores principales: Pipe, Steven W., Trzaskoma, Ben, Minhas, Miranda, Lehle, Michaela, Ko, Richard H., Gao, Ling, Mahlangu, Johnny, Kempton, Christine L., Kessler, Craig M., Kruse-Jarres, Rebecca
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2023
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9992752/
https://www.ncbi.nlm.nih.gov/pubmed/36908770
http://dx.doi.org/10.1016/j.rpth.2023.100077

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9992752/
https://www.ncbi.nlm.nih.gov/pubmed/36908770
http://dx.doi.org/10.1016/j.rpth.2023.100077

Ejemplares similares